Clinical Trial Update: The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the combination of toripalimab and temozolomide as neoadjuvant therapy for resectable stage III melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• toripalimab + temozolomide

Snippet

Sponsor: Yong Chen | Conditions: Melanoma Stage III | Phase 2 | Status: UNKNOWN